and safer drugs in a responsible fashion. Widespread patenting of deuterated analogues, however, in the hope that they have sufficiently "new" or different properties to satisfy the "non-obviousness" requirements of the U.S. Patent and Trademark Office, would have serious consequences. Publication of clinical data in peer-reviewed scientific journals will help make the case for the introduction of deuterated therapeutics for the most promising candidates. However, patenting these substances en masse for profit-making purposes rather than the advancement of medicine could have severe and unintended repercussions for forensic laboratories. 
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